M2sr Vaccine Technology: How Flugen Is Introducing New Solutions and Strategies for Influenza and COVID-19 Protection – Healthcare Business Today Article written by Paul Radspinner, featured in Health Care Business… read more →
FluGen’s M2SR vaccine shields against influenza and COVID-19 (drugdiscoverytrends.com) Article written by Pamuk Bilsel and Paul Radspinner, featured in Drug Discovery and Development February 7, 2023 For many years, vaccine… read more →
– Four leading pediatric infectious disease institutions will study M2SR vaccine response in pediatric subjects, a population in which infection rates are often highest – – Collaborative study led by… read more →
– Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population – – Funded by the… read more →
MADISON, Wis., January 5, 2022 – FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced that the Company will present at the 40th Annual… read more →